A Study of Sovilnesib in Subjects With Ovarian Cancer

Running, not enrolling · Phase 1

Conditions studied: High Grade Serous Adenocarcinoma of Ovary, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Chromosomal Instability

In brief

This is a randomized, phase 1b study to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of sovilnesib at different dose levels to establish the Recommended Phase 2 Dose (RP2D) of sovilnesib in subjects with high grade serous ovarian cancer (HGSOC).

Key facts

Study ID

NCT06084416

Run by

Volastra Therapeutics, Inc.

People needed

120

Starts

2024-04-04

Expected to finish

2026-04-01

Last updated by the study team

2025-10-20

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

Where it is running

• The University of Alabama at Birmingham — Birmingham, Alabama, United States
• University of Arkansas for Medical Sciences — Little Rock, Arkansas, United States
• UCLA — Los Angeles, California, United States
• Hoag Memorial Hospital — Newport Beach, California, United States
• Georgia Cancer Center Augusta University — Atlanta, Georgia, United States
• Johns Hopkins Hospital — Baltimore, Maryland, United States
• Dana Farber Cancer Institute — Boston, Massachusetts, United States
• Corewell Health — Grand Rapids, Michigan, United States
• Roswell Park Comprehensive Cancer Center — Buffalo, New York, United States
• Icahn School of Medicine at Mount Sinai — New York, New York, United States
• OU Health Stephenson Cancer Center — Oklahoma City, Oklahoma, United States
• MUSC Hollings Cancer Center — Charleston, South Carolina, United States
• Fred Hutchinson Cancer Center — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.